Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025

Core Viewpoint - Co-Diagnostics, Inc. is set to participate in Nasdaq's Live from MarketSite broadcast, highlighting its innovative molecular diagnostic tests and future health crisis preparedness [1][2]. Company Overview - Co-Diagnostics, Inc. is a molecular diagnostics company that develops and markets advanced diagnostic technologies, focusing on nucleic acid detection and analysis [7]. Product Pipeline - The upcoming Co-Dx PCR platform will include tests for COVID-19, tuberculosis, HPV, and an upper respiratory multiplex panel, with a focus on addressing future infectious disease threats [2][6]. - The Co-Dx™ Logix Smart® ABC Test detects all known circulating strains of H5N1 and is available as a Research Use Only assay in the U.S. and as an in vitro diagnostic in CE-marking regions [3]. - An updated 3-gene version of the Co-Dx™ Logix Smart® Mpox test is prepared for launch, retaining full reactivity against circulating mpox strains [4]. Market Context - A post-holiday surge in COVID-19 cases indicates the virus remains a persistent threat in the U.S., emphasizing the need for continued vigilance and effective diagnostic solutions [5].